UNASSIGNED: In this study, we retrospectively examined whether HBO therapy affects the prognosis following CD infections (CDI). This study included 92 inpatients diagnosed with CDI at our hospital between January 2013 and December 2022. Of these, 16 patients received HBO therapy. The indications for HBO therapy were stroke in five patients, ileus in four patients, cancer in two patients, acute peripheral circulatory disturbance in two patients, and others in three patients. The mean observation period was 5.4 years.
UNASSIGNED: In the univariate analysis, there was no significant difference in severity, mortality, hospitalization, or overall survival between patients who did and did not receive HBO therapy. However, the HBO group had a significantly lower recurrence rate (0% vs. 22.4%, p=0.0363) and a shorter symptomatic period (6.2 vs. 13.6 days, p=0.0217).
UNASSIGNED: HBO may have beneficial effect on CDI by shortening the symptomatic period and preventing recurrence.
■在这项研究中,我们回顾性研究了HBO治疗是否会影响CD感染(CDI)后的预后.这项研究包括2013年1月至2022年12月在我们医院诊断为CDI的92名住院患者。其中,16例患者接受HBO治疗。HBO治疗的适应症是5例患者中风,四个病人的肠梗阻,两名患者的癌症,两名患者的急性外周循环障碍,和其他三个病人。平均观察期为5.4年。
■在单变量分析中,严重程度没有显着差异,死亡率,住院治疗,或接受和未接受HBO治疗的患者的总生存期.然而,HBO组的复发率明显降低(0%vs.22.4%,p=0.0363)和较短的症状期(6.2vs.13.6天,p=0.0217)。
■HBO可能通过缩短症状期和预防复发而对CDI产生有益作用。